CD38 Antibody Daratumumab as an Add-On Rescue Therapy for AMR - First Report in Clinical Lung Transplantation

Purpose: Antibody-mediated rejection (AMR) following lung transplantation (LTx) poses a major threat to allograft function. Current treatments focus on depleting circulating antibodies and suppressing B-cell activity, but often fail to reduce donor-specific antibodies (DSAs) adequately. Daratumumab, a monoclonal antibody that targets CD38 and depletes plasma cells and NK cells, could potentially improve AMR outcomes. Herein, we report the first use of daratumumab in the setting of lung transplantation.

Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , S. Auner, D. Koren, G. Fischer, Z. Kovacs, P.M. Boehm, C. Aigner, K. Hoetzenecker, F. Calabrese, P. Jaksch, A. Benazzo Source Type: research